0000000000955232

AUTHOR

G Mazziotti

showing 2 related works from this author

Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

2014

Guidelines for the management of osteoporosis induced by endogenous hypercortisolism are not available. Both the American College of Rheumatology and the International Osteoporosis Foundation recommend to modulate the treatment of exogenous glucocorticoid-induced osteoporosis (GIO) based on the individual fracture risk profile (calculated by FRAX) and dose of glucocorticoid used, but it is difficult to translate corticosteroid dosages to different degrees of endogenous hypercortisolism, and there are no data on validation of FRAX stratification method in patients with endogenous hypercortisolism. Consequently, it is unclear whether such recommendations may be adapted to patients with endoge…

Oncologymedicine.medical_specialtyFRAXEndocrinology Diabetes and MetabolismOsteoporosisHypercortisolismAdrenal incidentaloma; Cushing's disease; Glucocorticoids; Osteoporosis; Bone Density Conservation Agents; Cushing Syndrome; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Risk FactorsEndogenyDiseaseadrenal incidentalomaBone remodelingRisk FactorsInternal medicinemedicineHumansCushing SyndromeBone Density Conservation Agentsglucocorticoidsbusiness.industrycushing's diseaseCushing's diseasemedicine.diseaseosteoporosisRheumatologyglucocorticoids; osteoporosis; cushing's disease; adrenal incidentalomaEndocrinologyAdrenal incidentaloma; CUSHING'S DISEASE; Glucocorticoids; OsteoporosisbusinessGlucocorticoidOsteoporotic Fracturesmedicine.drug
researchProduct

The hypertension of Cushing's syndrome: Controversies in the pathophysiology and focus on cardiovascular complications

2014

Cushing's syndrome is associated with increased mortality, mainly due to cardiovascular complications, which are sustained by the common development of systemic arterial hypertension and metabolic syndrome, which partially persist after the disease remission. Cardiovascular diseases and hypertension associated with endogenous hypercortisolism reveal underexplored peculiarities. The use of exogenous corticosteroids also impacts on hypertension and cardiovascular system, especially after prolonged treatment. The mechanisms involved in the development of hypertension differ, whether glucocorticoid excess is acute or chronic, and the source endogenous or exogenous, introducing inconsistencies a…

Maleantihypertensive treatment; blood pressure; corticosteroids; Cushing's syndrome; hypercortisolism; hypertension; metabolic syndrome; vascular system; Animals; Blood Pressure; Cushing Syndrome; Female; Glucocorticoids; Humans; Hypertension; Male; Metabolic Syndromemedicine.medical_specialtyPhysiologyHypercortisolismReviewsCushing's syndromecorticosteroidsSettore MED/13 - EndocrinologiaCushing syndromeInternal medicineAntihypertensive treatmentInternal MedicineAnimalsHumansMedicineCorticosteroidIntensive care medicineCushing SyndromeGlucocorticoidsS syndromebusiness.industrymedicine.diseaseMetabolic syndromeantihypertensive treatment blood pressure corticosteroids Cushing's syndrome hypercortisolism; hypertension metabolic syndrome vascular systemPathophysiologyClinical trialCritical appraisalEndocrinologyBlood pressureVascular systemantihypertensive treatment; blood pressure; corticosteroids; Cushing's syndrome; hypercortisolism; hypertension; metabolic syndrome; vascular systemHypertensionBlood pressureFemaleAntihypertensive treatment; Blood pressure; Corticosteroids; Cushing's syndrome; Hypercortisolism; Hypertension; Metabolic syndrome; Vascular system; Internal Medicine; Physiology; Cardiology and Cardiovascular MedicineMetabolic syndromebusinessCardiology and Cardiovascular MedicineGlucocorticoidmedicine.drug
researchProduct